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Abstract
The risk adjustment model currently used does not adequately compensate
insurers for predictable differences in individuals’ health care expenditures in
the Czech Republic. It then leads to financial inequality in the redistribution of
funds to the insurance companies and causes their financial problems. This study
introduces a PCG model as another method for risk adjustment and determines
to what extent the predictive performance of the model can be improved when
applied to Czech data. We analyze 10% of population sample in the Czech
Republic in years 2011 and 2012. Our results confirm the appropriateness of the
PCG model for the Czech environment. When the PCG variables are added to
the demographic model, R2 value of the prediction model increases from 2.03%
to 13.87%.
JEL Classification I13, I18,
Keywords PCG model, health insurance, prediction of
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Abstrakt
Současný model kompenzace rizika v České republice nedostatečně odráž́ı
variabilitu predikovatelných náklad̊u na zdravotńı péči jednotlivých pojǐstěnc̊u,
č́ımž docháźı k finančńımu znevýhodněńı některých pojǐstoven. Tato práce
rozv́ıj́ı metodiku farmaceutických skupin (PCG model) a analyzuje přinos jejich
zařazeńı do českého modelu, který je v současnosti použ́ıván. Pro analýzu jsou
použita data 10% vzorku české populace v letech 2011 a 2012. Výsledky práce
potvrzuj́ı vhodnost PCG modelu pro české prostřed́ı. Zařazeńım PCG skupin
do demografického modelu se R2 hodnota modelu zvýšila z p̊uvodńıch 2.03% na
13.87%.
Klasifikace JEL I13, I18,
Kĺıčová slova PCG model, zdravotńı pojǐstěńı, predikce
náklad̊u na zdravotńı péči, riziková úprava
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Motivation In the Czech Republic, the public health care system is financed
by insurance tax. The collected insurance funds are redistributed to the insur-
ance companies according to the total number of enrollees. As risk factors, their
gender and age are used. Significant risk of economic problems emerges for the
insurance companies when their enrollees consume more health care than is
predicted by the system.
There are other various approaches to evaluate and to predict medical costs in the
health care system. Pharmacy-based Cost Groups (PCG) is one of the methods
recently used. It is an outpatient morbidity measure based on information
about chronic conditions deduced from the use of prescribed drugs.
We argue that PCG might be a feasible option for improving the risk adjustment
system in the Czech Republic. Thus, the goal of this thesis is to examine whether
the current Czech model can be improved by incorporating information on the
presence of chronic conditions.
Hypothesis
1. Is the predictive performance of the PCG model for health care ex-
penditures in the Czech Republic better than the performance of the
demographic model? By how much?
Master Thesis Proposal xii
2. Risk-adjustment by including the region of origin of individuals improves
the predictive power of the model.
Methodology To apply the PCG model in the Czech environment, we will
use data of drug usage by insured persons, their demographic characteristics
and health care costs. To assign enrollees into PCG, we will basically use
classification defined by Lamers and van Vliet (2004) which might be further
adjusted to the Czech specifics of drug use.
Based on Lamers and Vliet (2003), firstly we will estimate the demographic
model currently used. In this model, the independent variables are age× sex
(18 × 2 = 36 dummy variables) and the dependent variable is health care
expenditures. Subsequently, we will estimate the PCG model. Therefore, the
demographic model will be extended for dummy variables for chronic conditions
based on previously defined classification. The model might be further modified
with dummy variables for regions (NUTS 3-4) where individuals live.
We will calculate the proportion of explained variation for each regression model
to assess their performance. Moreover, we will apply cost quintile analysis
as risk groups may generate more precise predictions for different ranges of
the cost distribution. (Fishman et al., 2003) Individuals will be grouped into
equally populated segments based on their actual costs, and each quantile will
be examining both statistically and graphically.
Expected Contribution A common challenge for health care reforms is
to find adequate predictors of health care expenditures, in particular direct
measures of health status among insured individuals. Different studies approved
that PCG model has a good predictive power e.g. Lamers (1999a), Huber
et al. (2013), Putnam et al. (2002). These results and implications may not be
transferable to countries with diverse structure of population and health care
system. Therefore, the contribution of our study is to apply the PCG model on
Czech data to find out its possible application in the Czech health care system
and its advantages over the currently used model.




(a) Czech demographic model
(b) PCG model
3. Empirical analysis
(a) Estimation of the demographic model
(b) Estimation of the PCG model




All over the world, health care systems come under great pressure. Confronted
with an increasing demand for health care, the health care expenditures continue
to rise in many countries. As a result, policymakers are investigating methods
to increase the quality and efficiency of care. There has been a growing belief
that many inefficiencies stem from flawed provider payment systems creating
perverse incentives for health care providers (Eijkenaar, 2013). In response,
improved risk adjustment methods are introduced in the reimbursement for
services.
Risk adjustment is a technique used to calculate the expected costs of treating
a specific group. The model uses information about the members of that group
to allocate funds among insurance companies that pay for health care of the
people. An efficient risk adjustment scheme compensates insurers for predictable
variation in individual health care expenditures between low-risk individuals
(e.g. the healthy) and high-risk individuals (e.g. the chronically ill).
In case the risk adjustment scheme is not defined fairly, it introduces both
efficiency problems as well as fairness problems. Under the former, the insurance
companies are motivated to select low-risk individuals to save resources, under
the latter insurance companies are overfunded by the government for low-
risk groups and underpaid for high-risk groups. The goal is to ensure that
an insurance company that attracts a sicker than average set of enrollees will
receive greater resources and vice versa. Previous research has shown that
past drug consumption is indicative of individual health condition and can
be used as a health status proxy in risk adjustment models. Such models
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have been reported to have higher predictive power than models bases solely
on demographic factors such as age, gender and geographic location (Lamers
and van Vliet, 2004; Fishman et al., 2003; Huber et al., 2013). Examples of
pharmacy-based models are those used in the Netherlands or Slovakia.
This thesis introduces a pharmacy-based method for risk adjustment: Pharmacy-
based Cost Group (PCG) model. PCG adjusters define chronic disease classes
inferred from the prescription of drugs. The comparison of PCG and demographic
model that is currently used in the Czech Republic is presented. We focus on
the estimation of the prediction models, with the aim of explaining variation
in individual health care expenses and to obtain accurate predictions, as far
as is possible. We will further examine a use of regional variables in the PCG
model. We argue that the demographic model currently used in the Czech
Republic does not adequately predict the individual health care expenses. The
PCG model and regional variables are expected to bring additional information
about individual health status condition. Therefore, the underlying assumption
is that using a PCG model and regional adjusters will substantially increase the
predictive power of the model.
The sample used for the empirical analysis consists of 10% of the Czech
population in 2011 and 2012. The proposed regression model includes de-
mographic, regional and PCG variables and is estimated by Weighted Least
Squares (WLS).
No profound analysis of PCG model and its application to the Czech system
is available. As the results from previous studies may not be transferable to
countries with a diverse structure of population and health care system, we will
evaluate the appropriateness of the PCG model for the Czech environment. We
will also analyze if the PCG model compensates health plans for the expected
costs associated with the disease burden of their enrollees more accurately than
the demographic model.
Thus, the thesis will answer the following questions:
1. Is PCG model valid prediction model of health care costs in the Czech
Republic?
2. Does the predictive power of PCG model increase when regional adjusters
are added?
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3. Do PCG and regional models lead to a positive financial impact on
insurance companies?
The remainder of this study is structured as follows. Chapter 2 describes risk in
health care and presents the risk adjustment methods including the demographic
and PCG models. Chapter 3 turns to describing the Czech health care system.
Chapter 4 reviews the recent literature. In Chapter 5 the data description is
presented, followed by methodology in Chapter 6. The results are summarized
in Chapter 7 and are further discussed in Chapter 8. Finally, we conclude our
findings and formulate points for further research in Chapter 9.
Chapter 2
Risk in Health Care
Policy makers across the world emphasize the importance of ensuring adequate
health care for all. A significant barrier to this objective emerges as the cost of
health care is frequently high relative to an individual’s income and health care
costs are not distributed evenly through the population. The health care cost
falls disproportionately on disadvantaged populations, which are more likely to
experience higher rates of unemployment and to have lower incomes that would
not cover their health care needs. One group where high health risks emerge is
the senior population. As the income of seniors is often low, it would not cover
their total health expenditures.
Health care expenditures are also characterized by both large random variation
as well as large unpredictable variation across individuals. At least 70-80% of
the variation in annual health care expenditures among individuals is funda-
mentally unpredictable. Among the factors that influence the predictable part
of the variation of health expenditures are age, sex, place of residence or past
expenditures (Van Vliet, 1992; Smith and Witter, 2004).
Variations in health care expenditures create the potential for substantial
efficiency gains due to risk reduction from insurance. It also raises important
concerns about fairness across individuals with different expected needs for
services (Culyer and Newhouse, 2000).
The solidarity principle, which is highly valued in Europe, implies that high-risk
and low-income individuals receive an implicit subsidy to increase their access to
health insurance coverage. In other words, both the high-risk and the low-risk
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individuals pay the same premium. This mechanism called risk-pooling can be
used to help spread the costs of health care over a population group (Roberts
et al., 2008).
2.1 Risk pooling
The World Health Organisation (WHO) defines risk pooling as ”the practice of
bringing several risks together for insurance purposes in order to balance the
consequences of the realization of each individual risk.” (Reinhardt and Cheng,
2000)
Pooling ensures that the risk related to financing health costs is borne by all
the members of the pool and not by each subscriber individually. Therefore, the
main purpose is to share the financial risk associated with health interventions
as an individual’s need for health care is uncertain. Nobody knows if one will
need costly health care in the future or if they will become poor. Uncertainty
about getting sick and/or becoming poor in the future may motivate even
the healthy and rich person to consider desirable some redistribution toward
disadvantaged groups today, as a hedge against the risk of being in need of such
transfers in the future.
The arguments supporting risk pooling in health care are primarily equity and
efficiency. The equity arguments reflect the view that individuals should not
face all the risk associated with their potential health care expenditure. The
pattern of a burden of disease is related to poverty: the poor are the ones most
in need for health care. Their low levels of income can result in an inability to
seek treatment when it is paid, or there might be adverse consequences from
seeking paid treatment (such as indebtedness). Thus, if the situation emerges,
they are guaranteed adequate treatment and do not pay its full cost. The
efficiency arguments emerge because pooling can help to improve population
health, increase productivity, and reduce uncertainty associated with health
care expenditure. With no pooling, poorer citizens might languish untreated
and become a burden on society (Smith and Witter, 2004).
The access to health care should not be guaranteed only in time when the patient
is in poor health, but also it should provide access to prevention. There are
many positive externalities from increasing access to prevention and treatment.
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Firstly, it limits the spread of infectious diseases. Secondly, considering the
access to health care in wider economic terms, when a population is in good
health, it leads to higher workforce productivity.
For the purpose of risk pooling and the process of collecting revenue, there
is a health insurance market. The funds for health care are collected from
the population (individuals and corporate entities) by a collection agent. The
funding mechanism differs in various countries and often includes taxation,
social insurance contribution, private insurance premiums or out-of-pocket
payments1.
After collecting the revenues, the funds are pooled i.e. all the prepaid revenues
are accumulated together, and then are redistributed according to the defined
allocation mechanism to the insurance funds. This contribution to insurance
companies’ budget associated with an insuree is called a capitation payment2
or premium subsidies. As the health care expenditures needs of citizens vary
considerably due to different individual health conditions, the capitation system
therefore employs methods of adjustment. These methods seek to adjust per
capita payments to reflect the relative expected health service expenditures for
fund members on the basis of personal characteristics. As the allocation is being
adjusted according to the risk profile of individuals, this process is referred to
as risk adjustment.
2.2 Risk adjustment
It is important to define risk adjustment scheme well to effectively allocate
the pooled funds to sickness funds. Thus, a system of risk-adjusted premium
subsidies or risk equalization across risk groups should be implemented (Van de
Ven et al., 2003) to ensure that each insurance fund has the correct relative level
of allocated resources for the population which is responsible for (Mossialos
et al., 2002).
The definitions of risk adjustment vary. Ellis (2008) defines risk adjustment as
1 More information on the financing mechanisms may be found on
http://ies.fsv.cuni.cz/sci/publication/show/id/3693/lang/en
2 Since payments are calculated on a per capita basis.
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the use of patient-level information to explain variation in health care spending,
resource utilization, and health outcomes over a fixed interval of time, such
as a year. Keenan et al. (2001) define risk adjustment as the adjustment of
premiums paid to health plans (or to insurance companies) based on a formula
employing individual level diagnostic and/or demographic information.
Risk adjustment in the health insurance market has developed from a concern to
prevent cream-skimming. Barros (2003) defines cream-skimming as selection by
providers (or entities responsible for health care provision) of those consumers
expected to be profitable, given the system of risk-adjusted capitation payments.
Because insurance funds are not allowed to refuse applicants, they have incentives
to use the more subtle forms of selection, which may have negative effects.
The insurance funds may provide poor service to the chronically ill and choose
not to contract with providers who have the best reputations for treating chronic
illnesses. In sum, selection may threaten good quality care for the chronically
ill (Van de Ven et al., 2003).
Proper risk adjustment is an essential pre-condition for gaining the benefits
of a competitive health insurance market. Risk-adjusted payments to health
insurance companies should reflect each individual’s expected cost of health
services utilization. An ideal risk adjustment model levels the playing field,
so that a insurance company is indifferent between accepting healthy or ill,
young or old, rich or poor enrollees, because they are paid for the enrollees
expected risk. Risk-adjusted capitation payments should therefore encourage
sickness funds to concentrate more on cost-containment and efficiency instead of
focusing on risk selection. The risk-adjusted capitation payments should explain
predictable variations in annual per person health care expenditures, as far as
these are related to health status. Among the risk adjusters commonly used
are demographic and socioeconomic characteristics and health status proxies
using the pharmaceutical or diagnostic information.
2.3 Risk adjustment methods
Among the risk adjusters commonly used are demographic and socioeconomic
characteristics and health status proxies using the pharmaceutical or diagnostic
information.
2. Risk in Health Care 8
2.3.1 Demographic model
The demographic model uses as risk adjusters the individual age and sex
categories. Dummy variables are used for the various age/sex categories. The in-
dependent variables used in demographic models are degree of urbanization,
region, disability or employment status.
Various studies have shown that demographic variables are too crude as risk
adjusters. The capitation system can be improved by extending the set of risk
adjusters with measures that are more directly linked to health (Lamers and
van Vliet, 2004).
2.3.2 Diagnosis-based models
The essence of diagnosis-based models is to classify individuals into cost groups,
based on a limited set of diagnoses from hospital admissions in the preceding
year.
The Diagnostic Cost Groups (DCGs) were developed in the United States by
Ash et al. (1990). They developed DCG using empirically determined similari-
ties in the future costs of individuals hospitalized for different reasons. They
aggregated codes of International Classification of Diseases, 9th Revision, Clini-
cal Modification (ICD-9-CM) into nine diagnostic subgroups. The DCG model
improved R2 value to 4.5% compared to the value of 0.5% for the demographic
model. This model was further enhanced as described in Ellis et al. (1988); Ash
(1997).
Pope et al. (2000) set a new DCG-HCC clinical classification system. This DCG-
HCC system classifies each of the ICD-9-CM codes into diagnostic grouping called
DxGroups. These groups are further aggregated into Hierarchical Condition
Category (HCC) based on major diseases that are similar both clinically and
costly. This mechanism of aggregation is presented in Figure 2.1.
Pope et al. (2000) reported the R2 value of 11.2% for the DCG-HCC models
compared to the 1% when only the demographic variables are used.
In Europe, the DCG methodology was applied in Lamers (1999b) which compared
the demographic model, DCG model based on one year of observation and also
DCG model based on three years of observation. Demographic model reported
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Figure 2.1: DCG aggregation of ICD-9-CM codes
Source: Pope et al. (2000)
R2 value of 3.78%, DCG model of one year 6.48% and DCG model based on three
years 8%. Prinsze and van Vliet (2007) combined DCG and PCG in a single
prediction model which again improved the R2 value to 22.8%.
2.3.3 Pharmacy-based models
A weakness of the demographic model is that predicted expenses are not adjusted
for the large differences in individual health within each age/sex group. A way
to improve the predictions is to extend the set of risk adjusters with health
status proxy (Van de Ven et al., 2004).
Pharmacy-based models assume that the prescription data well captures the mor-
bidity conditions. The type of medication reveals the severity of the condition
being treated, and the filled prescriptions also represent the conditions that were
judged by the patient to be serious enough to seek treatment. These conditions
suggest that these chronically ill patients will require ongoing treatment and
subsequently higher expenditures. Therefore, the prescription data is considered
to be a reliable instrument for predicting future health care utilization (Kuo
et al., 2011).
Several pharmacy-based morbidity measures have been developed and applied
for predicting health care utilization. The Chronic Disease Score (CDS) is the
very earliest one and was designed by Von Korff et al. (1992) in the United
States. It used data only for an adult population. The authors established a set
of dummy variables that indicate a pharmacy prescription during a base period
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for a medication representing particular chronic diseases. In total 28 different
conditions were distinguished. This score was evaluated in terms of its stability
over time and its association with other health status measures. It predicted
hospitalization and mortality in the following year after controlling for age and
gender and moreover CDS showed a high year to year stability. This CDS model
containing 28 binary variables together with age and sex explained 10% of the
variation in total health expenditures of adults enrolled in a health maintenance
organization in the next 6-month period. Age and sex alone (demographic
model) explained 3% of the variation in total charges.
Fishman and Shay (1999) focused on the evaluation of a pediatric risk as-
sessment model for children population in the period 1992-93 and developed
Pediatric Chronic Disease Score (PCDS). They employed a methodology similar
to that used in the development of the CDS. Drugs commonly used in ambu-
latory settings for the treatment of specific chronic conditions were grouped
into 26 diagnostic categories. The model including PCDS explained 17% of
the prospective individual variation in costs and significantly outperformed
the demographic model with R2 equal to 1.4%.
Fishman et al. (2003) revised and expanded the CDS and PCDS. The original
established CDS was not intended as a capitation payment adjuster. Hence, it
included several categories that authors found inappropriate in a model used
for financial purposes as some drugs are prescribed less systematically e.g. pain
drugs. The new model, called RxRisk, was an all-ages and market segment
pharmacy-based risk assessment model. Fishman et al. (2003) used total costs as
a proxy for medical risk. They assumed that medical risk during the examined
time period is a function of each individual’s age and sex, the source and extent
of their health insurance (commercial, Medicare, or Medicaid) and the set of
chronic conditions they are being treated for. These chronic conditions were
measured by the RxRisk algorithm during a previous period, an updated CDS.
RxRisk had an R2 of more than 9% for the estimation sample. The demographic
instrument explained relatively little of the prospective variance in cost with
an R2 of 3.9%.
These pharmacy-based risk adjustment tools have been tested and were found
to be valid in predicting future health care utilization in the US, but most of
them incorporate a coding algorithm that is specifically designed for the United
States. Kuo et al. (2011) verified that the approaches incorporating a coding
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algorithm that requires the medication data to be coded using the US National
Drug Codes or the American Hospital Formulary Service drug codes can be
applied also with Anatomical Therapeutic Chemical (ATC) algorithm and are
able to explain the variations in health care utilization. This study also revisited
the CDS by adding new medications to the original morbidity classes, and by
included new disease categories which may be more appropriate to capture
morbid conditions for different ethnic populations. The performance of the
pharmacy-based metric model was tested using a sample representing the entire
population of Taiwan. The resulting R2 in the demographic model was only
3.5% whereas in case of model including pharmacy-based metric was 15.1%. By
adding Elixhauser’s comorbidity index3 to the model, R2 rose to 19.2%. The
study also compared the pharmacy based metric with diagnosis-based models
and found out that pharmacy based models explain or predict the health care
costs better.
PCG model
The PCG model works on the assumptions of the CDS that drug consumption is
a valid predictor of health care expenditures. The PCG model further adjusts
the CDS for the European health specification. In Europe, the ATC coding is
used. Therefore, prescription drug items are coded based on the WHO ATC
classification system (Huber et al., 2013).
The PCG is an outpatient morbidity measure based on prior use of prescribed
drugs. According to the PCG model, ATC codes are assigned to different
chronic diseases. The essence of the risk adjustment using PCG is that enrollees
are classified into clinically homogeneous groups based on the prior use of
pharmaceuticals. Using the ATC classification system, the active substances are
divided into different groups according to the organ or system on which they
act and their therapeutic, pharmacological and chemical properties.
Lamers (1999a) adjusted the US classification of medications representing
chronic conditions that underlies the PCG model to the Dutch situation. He
3 A comorbidity index based on an approach to identifying comorbidities and separates them
from the primary reason for hospitalization. It results in an expanded set of comorbidities.
It should be used carefully as an index because comorbidities affect outcomes differently
among different patient groups (Elixhauser et al., 1998).
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extended the study on the CDS using automated outpatient pharmacy data
of one Dutch sickness fund. The 28 original chronic conditions were clustered
into seven PCGs according to empirically determined similarities in future costs.
The clustering of conditions into these seven PCGs almost did not affected the
predictive power of the model. The PCG model explained 10% of the differences
in next year’s expenditures between individuals, which was almost twice the R2
of a model containing only demographic variables.
Lamers and van Vliet (2004) newly derived the classification of drugs (see
Table 2.1) and used it to estimate a capitation model containing demographic
variables and information on chronic conditions. Based on these ATC-codes,
persons with claims for medications were assigned to 20 chronic conditions.
A demographic model alone explained 5.0% of the differences in health care
expenditures in 1998 among individuals. The R2 value of the chronic conditions
model was 9.2%.
Table 2.1: Pharmacy-based cost groups
Chronic
condition
ATC-code Description of ATC-code
Epilepsy N03A (excluding N03AE01) Antiepileptics


































Parkinson’s disease N04B Dopaminergic agents
Renal disease B03XA01, V03AE01 Erythropoietin, polystyrene
suplhonate
Continued on next page
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Table 2.1: Pharmacy-based cost groups (Continued)
Chronic
condition
ATC-code Description of ATC-code
Cardiac
disease/ASCVD/CHF
C01 Cardiac therapy: Cardiac
stimulants and glycosides,
Antirrhythmics: class I and III,
vasodilators used in cardiac diseases
C03C, C03EB01 High-ceiling diuretics
Glaucoma S01E Antiglaucoma preparations
Peptic acid disease A02A, A02B Antacids. drugs for treatment of
peptic ulcer
Cystic fibrosis A09AA02 Multienzymes
Transplantations L04AA01/5/06, L04AX01 Ciclosporin, tacrolimus,
mycophenolic acid, azathioprine
Respiratory illness, asthma R03 Antiasthmatics
Thyroid disorders H03A, H03B Thyroid preparations,
Antithyroid preparations
Gout M04A Antigout preparations
Crohn’s and ulcerative colitis A07EC (excluding A07EC01) Mesalazine, olsalazine






Diabetes I A10A Insulins
Diabetes II A10B Oral blood glucose lowering
drugs
The PCG model should identify only chronically ill people and should not include
the prescription addressed to a minor temporary health problem. The studies
of Lamers (1999a); Lamers and van Vliet (2004) classified a person to a PCG
based at least on four prescriptions per year. Lamers and Vliet (2003) used
as a threshold prescribed sum of Defined Daily Doses (DDD) comparing the
thresholds of 91 DDD and 181 DDD. Using DDD eliminates the possible form of
manipulation in this context e.g. a patient could receive four times a prescription
for 1 week instead of a prescription for a whole month.
Huber et al. (2013) updated the model to the Swiss environment and created
a model including 22 chronic conditions, age, sex, language area, managed care,
deductible and accident coverage as independent variables to predict to total
health care cost. They used two-part regression models. In the first part, logistic
regression si used to determine the probability of incurring health care costs
per patient/year. In the second part, Generalized Least Squares (GLS) with
gamma error distribution and linear link function were used to estimate annual
health care expenditures. They calculated the expected total health care costs
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by multiplying predicted values from the first and second stage. The model
explained 17.9% for the people aged 18-65years and 14.1% for persons aged 65
years and up. The model again outperformed the demographic model which
reached R2 of 2.5% and 6%, respectively.
Table 2.2 summarizes the application of different pharmacy-based models in
the literature.





Sample Variables Method R2
US Von Korff et al. (1992) CDS adult 28 chronic groups,
age, sex
OLS 10%
US Fishman and Shay (1999) PCDS children 26 chronic groups,
age, sex
OLS 17%































Our analysis will compare the PCG model with the demographic model currently
used in the Czech Republic. The reason we have decided to explore the PCG
model carefully is that it yields significant improvements in the prediction
accuracy. Moreover, it is easy to implement as the data of drug consumption
are available in the Ministry of Health.
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2.4 Risk adjustment in other European coun-
tries
Risk adjustment is applied differently in various health care systems. In the
next sections, we describe several advanced systems of risk adjustment used in
the present.
2.4.1 The Netherlands
The Netherlands is the pioneer in risk adjustment in Europe. It serves as
a model for other countries (Van Kleef et al., 2013).
The Netherlands has implemented the risk equalization model since 1993. Within
the current scheme, a prospective payment is made to insurers for each enrollee
on their list, depending on risk characteristics of that enrollee. The follow-
ing risk characteristics were added to the model: age interacted with gender
(1993), region (1995), source of income interacted with age (1999), PCGs (2002),
diagnoses-based cost groups (2004), socioeconomic status interacted with age
(2008) and prior multiple-year high costs (2012). Overall there was 126 risk
classes in 2012.
The current model comprises 40 classes for age and gender (20 classes for men
and 20 classes for women). The age classes are 0, 1-4 and then 5-year groups up
to the age of 90 and finally a class for people of 90 years and older. In addition,
the model includes 10 clusters of regions. This urbanization criterion divides
about 4000 Dutch postal codes into ten different groups, and this allocates every
Dutch person uniquely to one of the ten groups.
The model also includes 17 classes for source of income, interacted with age.
The following four sources of income are distinguished: self-employment, disabil-
ity benefits, social security benefits and other (including employment). Each
of these groups is interacted with age groups 18-34, 34-44, 45-54 and 55-64
years. Enrollees in the age groups 0-17 and 65 years or more are classified in
one separate class.
The first direct proxy for health status used 26 PCGs. Enrollees are categorized
in one or more of the PCG if they received at least 180 DDD of a certain
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pharmaceutical in the preceding year. People who are not classified to any
PCGs are assign to a group ”no PCG”. An individual can be classified to more
than one PCG. As another direct proxy for health status, the model includes 14
DCGs. Using DCGs, individuals are classified into cost groups based on inpatient
diagnoses from the previous year. Insurees with multiple diagnoses are classified
in only one DCG (that with the highest costs). In 2013, the Dutch government
made the DCGs also dependent on diagnostic information from prior outpatient
visits in hospitals (not only outpatient). Each enrollee can be classified into one
DCG at the maximum.
Furthermore, the model comprises 12 classes for socioeconomic status, interacted
with age. This classification is based on income, a number of household members
and age. For each enrollee, the income level is calculated as the household
income divided by the number of household members. There are three groups:
the bottom 30% of the income distribution, the middle 30-70% and the top 30%.
Enrollees living in a household with more than 15 members are classified into
a class independent of their income (the assumption being that they are living
in a nursing home, an institution for handicapped or similar facility. Each of
these socioeconomic classes interacts with three age groups (0-17, 18-64 and 65
years and more).
Since 2012, the model includes separate classes for enrollees with high costs
in three previous years as those with high cost probably suffer from a chronic
disease. Enrollees are classified into six cost groups if their health care expenses
in year t-1, t-2 and t-3 are in top 1.5%, 4%, 7%, 10% or 15%.
The value of R2 reaches 29.6% for the Dutch model (Van Kleef et al., 2013).
2.4.2 Germany
Originally, risk adjustment between the insurance funds in Germany was based
on socio-demographic factors: age, sex, invalidity pension status and type of
entitlement for sickness allowances.
There are single-year age groups up to 90 years for calculating standardized
expenditures separately for men and women. The recipients of invalidity pension
form another risk class. The entitlement for sickness allowances creates other
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three groups: no entitlement, entitlement after 6 weeks and entitlement from
the first day of absence from work.
In 2009, the new risk adjustment scheme was implemented called DCG-HCC
model. This model separates DCGs into disease hierarchies that allow classifying
individuals with multiple (unrelated) diagnoses into multiple risk classes4. There
are 50-80 diseases selected which has to exceed 1.5 times the average per capita
expenditure of all insured (cost threshold). There are 366 diseases based on the
781 DCGs of the HCC classification model. Furthermore, there are two criteria
to be fulfilled in order to distinguish only severe and chronic diagnoses:
1. a disease has to be diagnosed in at least two different quarters of the year
of observation in at least 50% of cases
2. at least 10% of the cases had to be hospitalized
After applying these criteria, the 80 most expensive diseases are selected and
integrated into the risk adjustment model.
The R2 value of the model was 23.9% in 2011 (Buchner et al., 2013).
2.4.3 Slovakia
Slovakia is a country that has recently introduced a PCG model into practice.
Initially, the risk adjustment system distinguished only the economical active
and inactive insured persons between 1995 and 2004. With the reform in 2004,
the age and gender were introduced as risk adjusters. The age cohorts were
divided by five years up to the age of 80 and again interacted with sex. In 2012,
the economic activity status was added, and the PCG system was introduced.
The Slovakian system used 24 PCGs in 2014. The threshold number of DDD is
181, the same threshold as used in the Netherlands. The Slovakian system does
not allow comorbidity. In case that a person is classified into more than one
PCG, only the most expensive group is taken into account.
Adding PCGs to the risk adjustment model raised the predictive power of the
model from 3.19% to 19.58% (Szalayova, 2012).
4 It is different to the Dutch model where diagnoses are grouped in DCGs only by similarities
in follow-up costs and individuals can be classified in one DCG only.
Chapter 3
Czech Health Care System
The Czech Republic has a system of social health insurance based on compulsory
membership in one of the health insurance funds. It is characterized by high
level of solidarity which means that the health care provided is at the same
level for everybody regardless how much he contributes.
The social health insurance contributions are wage-based payments paid by
employers, employees, self-employed individuals and for groups of inactive people
(unemployed, students, retired people, . . . ) paid by the state.
3.1 History of the Czech health care system
Czech (and, at that time, also Slovak) health care was characterized by universal
coverage, national tax financing along with national ownership and control of
health providers. The new system of compulsory social health insurance was
introduced in 1992. The insurance was initially managed by a single insurer
the General Health Insurance Company - Všeobecná zdravotńı pojǐsťovna
(VZP), which was responsible for collection and pooling of premium, as well as
purchasing health care services for the entire population. Parliament approved
another law enabling the foundation of competing non-profit making insurers
established as public institutions in 1992. The first started operating in 1993.
They were primarily organized around large employers or by industry sectors
and were thus called branch or employers’ health insurers. Their number reached
27 in 1995 and then decreased rapidly as many of them experienced financial
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problems (Kutzin et al., 2010). By the year 2012, the number of insurers
stabilized at seven (Table 3.1), but 59% of the population still belongs to the
VZP.
Table 3.1: Czech insurance companies
ID Insurance company
111 Všeobecná zdravotńı pojǐstovna
201 Vojenská zdravotńı pojǐsťovna
205 Česká pr̊umyslová zdravotńı pojǐsťovna
207 Oborová zdravotńı pojǐsť. zam. bank, poj. a staveb.
209 Zaměstnanecká pojǐsťovna Škoda
211 Zdravotńı pojǐsťvna ministerstva vnitra ČR
213 Rev́ırńı bratrská pokladna, zdrav. pojǐsťovna
217 Metal-aliance
The subscribers to the branch insurers were primarily employed citizens and
relatively younger and healthier individuals, retired and non-active citizens
stayed subscribed to VZP. As each insurer collected premium (set as a payroll
tax) independently, the difference in the risk composition of membership caused
a rapid deterioration of the financial situation of the VZP. Therefore, the
maintenance of isolated pools became unsustainable.
In 1994, a national pooling arrangement was introduced through a simple
risk-adjustment mechanism administered by the VZP. Approximately 70% of
collected funds - 60% of collected premiums and the whole payment from the
state budget on behalf of non-working people (state insurees) - were subject to
redistribution between insurers. The funds were redistributed between insurers
according to the number of state insurees enrolled with each of the insurers
with adjustment for age. Within the state insurees, two age categories were
recognized - below and above 60 years and were assigned different weights in
the risk adjustment formula. The group above 60 years was used with a triple
weight than the younger group.
This arrangement enabled a more equitable division of available resources
between the VZP and other health insurers, but it did not eliminate incentives
for cream-skimming. Enormous differences (up to 50%) existed in average
premiums collected from the economically active population, thus presenting
an important disadvantage for insurers with higher shares of lower-income
insurees. The age structure of the VZP’s clients, combined with the low level
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of state premium payments, contributed to its repeated deficits. Conversely,
the other insurers reported mostly positive or at least neutral results.
From 2004 to mid-2006, a new risk-adjustment process was gradually imple-
mented. Since then, all collected funds are subject to redistribution that
combines a more refined ex-ante formula and an ex-post partial compensation
of expensive cases.
3.2 Current situation in the Czech Republic
The reform of 2004 introduced complete pooling of the state payment and all
collected premiums, which are redistributed among insurers on a capitation
basis. The pooling mechanism is captured in the Figure 3.1
Figure 3.1: Pooling mechanism of funds
Source: Kutzin et al. (2010)
The new capitation formula is based on age (grouped into 5-year categories)
and on gender, forming a total of 36 groups. Each year, Ministry of Finance
and Ministry of Health issue new regulation with cost indices (weights) for each
age/gender group which determine the redistribution of funds to each insurance
funds depending on their composition of policyholders.
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Each insurer reports the total amount of its collected premiums, as well as the
number and age structure of its insured individuals on a monthly basis. State
payments for economically non-active citizens flow directly to a special account
operated by the VZP under the supervision of other insurers and the Ministry of
Health and Finance. The account’s manager then calculates the total amount
of income (collected premiums + state payment) per ”standardized” insured
individual (woman aged 15-20 years). The amount of money allocated to each
insurer then reflects the age/sex structure of the insuree.
The cost indices for the year 2015 are summarized in the Table 3.2.
Table 3.2: Cost indices
Age group Cost weights
From To Man Woman
0 5 1.4572 1.3104
5 10 0.8549 0.7337
10 15 0.8500 0.9178
15 20 0.7680 1
20 25 0.6433 0.9771
25 30 0.7293 1.2726
30 35 0.8143 1.4144
35 40 0.9038 1.3463
40 45 1.0329 1.3542
45 50 1.2482 1.5727
50 55 1.5980 1.8583
55 60 2.1939 2.1331
60 65 2.8450 2.4374
65 70 3.6289 3.0240
70 75 4.2934 3.5835
75 80 4.8464 4.1361
80 85 4.9879 4.5522
85 and more 5.1021 4.9410
Source: 2012, Directive n. 442/2012 Sb.
Cost indices are determined as a share of average costs of an insured individ-
ual in the age/sex group when the costs of expensive clients5 are subtracted.
The average costs in each group are set as an average costs of all insurance
funds for an insuree in the group. The average costs of a standardized insuree
5 Their costs are 25 times higher than the average cost.
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are determined as an average of costs of all insurance funds for a women aged
15-20 years.
In addition, the system includes an ex-post partial compensation of expensive
clients. If the annual costs of an insured individual are 25 times greater than
the average annual costs per client in the entire social health insurance system,
the insurer is compensated for 80% of the costs over the limit once a year i.e.
when the previous year’s financial results are published. This compensation is




The efficiency of different risk adjustment models has been widely assessed in the
literature. The linear regression model using the Ordinary Least Squares (OLS)
and WLS estimators has been commonly used (Fishman et al., 2003; Lamers and
van Vliet, 2004; Zhao et al., 2005; Van de Ven et al., 2014). Applying OLS models
on untransformed data for predicting individual expenses has been however
discussed widely (Mihaylova et al., 2011; Lin, 2008; Jones, 2010), because OLS
may not fit the distributional properties of health care expenses very well.
Jones (2010) and Veazie et al. (2003) assert that medical expenditures typically
feature a spike at zero (i.e. nonusers) and a strongly skewed distribution with
a heavy right-hand tail. This non-normality stems from the fact that, due to
clinical complications and comorbidities, only a small minority of patients attract
substantial and costly services. Their individual treatment is very expensive,
creating outliers in the right-hand tail of the distribution. In econometric
models of health care costs, the error term will be heteroskedastic reflecting the
heterogeneity across patients. Due to these characteristics, reliance on a linear
model estimated by OLS is inappropriate.
The presence of a substantial proportion of zeros in the data and a right-
skewed distribution for users has typically been addressed by using a two-part
model. This method distinguishes between a binary indicator, used to model
the probability of any costs, and a conditional regression model for the positive
costs (Huber et al., 2013; Powers et al., 2005).
Alternatively, the transformation of the dependent variable is used. The common
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transformation included the log-transformation, but the square-root transfor-
mation and other power functions are applied as well (Jones, 2010). Using
a transformation of cost data typically reduces skewness and, therefore, makes
the distribution more symmetric and closer to normality. Parameter estimates
from the regression of the transformed dependent variable are however on
a different scale while analyst typically want results expressed in terms of
actual costs. Re-transformation to the original scale is problematic due to re-
transformation bias. Dunn et al. (2003) claim that a smearing factor is therefore
necessary to apply which is problematic in cases involving heteroskedasticity
in the data on the transformed scale. Note that Ellis et al. (2013) criticized
the log-transformation for severe overestimation of the upper expenditure tail
for the re-transformed data (raw). They justify the use of OLS explaining that
the mean prediction absolute error from the log model was twice that from
OLS.
Manning and Mullahy (2001) applied the Generalized Linear Models (GLM) for
the health care cost modeling, which accommodates skewness through variance
weighting. The advantage of GLM approach is that it does not require any
retransformation (as needed in log-transformed OLS), the dependent variable is
an expected value and is modeled on its original scale (Lin, 2008). According
to Ellis et al. (2013) however GLM substantially reduces the weight that is put
on observations with very high expenditures.
Powers et al. (2005) performed a comparative study of currently used models
(OLS, log-OLS, logistic/OLS two-part model, logistic/log-OLS two-part model,
logistic/GLM two-part model) and demonstrated that simple OLS model per-
form equivalently, in some cases with superiority to the variety of advanced
econometric models presented in his study. The R2 values for the log-OLS
model, logistic/OLS, logistic/GLM two-part model was lower compared to
the OLS method and when compared with the logistic/log-OLS two-part model
the R2 values were similar.
Supporting Powers et al. (2005), Fishman and Shay (1999) concludes that OLS
regression performs well as a forecasting model relative to more sophisticated
functional forms as it always yields unbiased estimates of parameter means.
Wooldridge (2012) explains that heteroscedasticity does not cause bias or
inconsistency in the OLS estimators, and the R2 is also unaffected by the
presence of heteroscedasticity. On the other hand, the estimates of the variance
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are biased. Since the OLS standard errors are based directly on their variances,
they are no longer valid for constructing the confidence intervals and t-statistics
which then needs to be considered during the analysis. When a large sample is
considered, non-normality is not a problem (Greene, 1997).
Health systems are country-specific. The results and implication of the previous
studies may not be directly transferable to the Czech health care system. Unfor-
tunately, no sophisticated analysis of risk adjustment mechanisms is available
in the Czech environment. Thus, our study will contribute to the existing
literature by comparing two methods of risk adjustment i.e. demographic model
and PCG model, using data from the Czech health care system.
Chapter 5
Data
This chapter describes the data set, variables used and provides descriptive
statistics.
5.1 Data description
The empirical analysis is based on a sample of 1 058 197 observations in the
period 2011-2012 which represents 10% of all enrollees in the Czech health insur-
ance program provided by the Czech Ministry of Health. Heath characteristics
included annual health care expenditures in CZK and information about the
number and type of prescribed drugs. Each drug had a specific ID, which is
assigned by the State Institute for Drug Control (SUKL). The Ministry also
provided us with the information on ATC specification and its DDD for each
drug. Demographic characteristics included sex, date of birth, region and also
the insurance company of the individuals.
5.1.1 Health care cost
The dependent variable in each of the estimated models is individual annual
health care expenditure. As in Lamers and van Vliet (2004), for each partial-
year enrollee who dis-enrolled or died during the given period, costs were raised
to annual rates and eligibility fractions were used as weights. For example,
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(b) Cost distribution in 2012
Figure 5.1: Cost distribution
assigned weight 0.5 and 20 000 annual expenses. By applying this procedure,
mean predicted expenses in year t equals mean observed expenses in year t.
Summary statistics of individual health care expenditures are presented in Table
5.1.
Table 5.1: Summary statistics of health care costs
Year Mean Std. dev. Min Max
2011 19 811 72 298 0 14 925 653
2012 20 285 75 123 0 15 157 077
The distribution of the costs up to 1 000 000 CZK in 2011 and 2012 is presented
in the Figure 5.1.
The costs are right-hand truncated at 1 000 000 in the Figure 5.1. Nevertheless,
the distribution still has a marked long right tail. Even if we lower the threshold
for truncation to 100 000 CZK, we find that only 3.16% of the sample exceeds
this threshold. This truncation was done only for the purpose to display better
the distribution (with larger-scale), but the further analysis in this study is
done on the whole sample to avoid the bias in the estimates.
There are some extremely expensive cases in the sample that might be considered
as outliers; nevertheless we keep them in the sample. Although removing outliers
observation would likely improve the overall fit of the models, it is not the
primary objective of our analysis. We assess the ability of the model to predict
the future total costs for high-cost health care participants that often contribute
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a disproportionate amount of cost to the system. This can by done only by
keeping the outliers in the estimation sample. (Powers et al., 2005)
5.1.2 Age and gender
In the current risk adjustment model used in the Czech Republic, 36 groups are
included to adjust for cost differences among age and sex groups. The population
is separated by sex and divided into 5-year intervals with two exceptions. Firstly,
the oldest age group comprises people aged 85 years and more consistent with
the current practice in the Czech Republic. Secondly, we decided to divide the
youngest group (0-5 years) into two categories: up to 1 year and 1 to 5 years.
The reason is that there is a significant difference between the average cost of
a newborn and the older children. This difference, as well as the differences
between costs of woman and men, are depicted in the Figure 5.2.
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Each group is included in the regression as a dummy variable with the exception
of woman aged 15 to 19 years which is a reference group in the analysis consistent
with the current practice in the Czech Republic. As the crucial date determining
the age is set the 30th of June 2010 for the analysis of the year 2011 and the 30th




Regions are risk factors commonly used in both capitation models (e.g. in
Switzerland or the Netherlands) and empirical works (Lamers and van Vliet,
2004; Huber et al., 2013). In our analysis, we will use the region of residence for
each insuree in the detail of NUTS26. The Czech Republic is divided into eight
NUTS2 regions which can be seen in the Figure 5.3. The number of regions
is comparable to the number of regions used in the risk model used in other
countries e.g. in the Netherlands. Observations where the regional code was
missing (n=2108, 0.2% of the sample) were dropped from the regression.
Figure 5.3: Czech Republic regions
Source: Regional council, edited by the author
The Table 5.2 shows the differences in mean health care costs among the regions
in 2011. These differences again suggest that regions might be valid adjusters
for health care costs. The highest average costs incurred the insurees living in
Prague (22 479 CZK), whereas the individuals living in Southwest region had
the lowest average cost (19 026 CZK).
Table 5.2: Average health care costs in the regions
Code NUTS 2 Average costs Population
CZ01 Prague 22 479 122 444
CZ02 Central Bohemia 20 302 127 974
CZ03 Southwest 19 026 121 144
CZ04 Northwest 19 031 113 592
CZ05 Northeast 19 593 152 430
CZ06 Southeast 19 129 169 283
CZ07 Central Moravia 19 129 123 587
CZ08 Moravia-Silesia 20 022 125 634
6 The original data set included region for each insuree in the detail of districts (NUTS4).
Including these 76 regional dummies might cause the model to be over-fitted, thus we
decided to use NUTS2 regions.
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5.1.4 Insurance companies
Table 5.3 displays the shares of population in 2012 registered with each insurance
companies. The proportion which belonged to the companies is comparable
to the values in our sample. Table 5.3 also summarizes the percentage of
chronically ill people (classification to the PCGs based on 121DDD) and mean
age, which are the leading factors of health care costs in our analysis. The
insurance companies with a higher number of chronically ill people had higher
expenditures on average. This fact confirms our hypothesis that a chronic
condition based on past consumption of drugs might be a good risk adjuster.
Nevertheless, this inference is not such straightforward. Each chronic condition
represents different diseases, thus incurs a different health care cost.












111 59.39% 60.09% 33.63% 43 21 507
201 6.01% 5.74% 28.07% 39 19 293
205 7.08% 6.98% 26.58% 37 17 934
207 6.71% 6.69% 26.32% 37 18 829
209 1.32% 1.29% 30.79% 39 19 286
211 11.37% 11.09% 27.93% 39 19 070
213 3.99% 4.09% 23.67% 36 16 927
217 4.13% 4.04% 25.17% 35 17 033
* http://www.mzcr.cz
Although the information about the insurance company which an individual
belongs to is not necessary for calculating the risk adjustment model, it is
important for evaluating the impact of the new model in practice. As mentioned
earlier the improper risk adjustment model might cause financial problems to
the insurance companies due to unfair allocation of money from the public
insurance.
5.1.5 PCG
The consumption of specific drugs is an indicator for the presence of a severe
disease. Only drugs prescribed specifically against certain chronic conditions
can be used to assign persons to a PCG which are subsequently used as risk
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adjusters. The codes from the prescriptions were first mapped to the WHO
ATC codes. ATC drug classes labeled with the 3rd to the 7th level of ATC
code are assigned to corresponding disease class (e.g. L02 Endocrine therapy
is assigned to the group Hormonal oncological treatment). Each drug or drug
class should only correspond to 1 disease category i.e. mutually exclusive.
To avoid the assignment of incidental users of drugs to chronic conditions,
persons were assigned to a PCG based on certain threshold. The most commonly
used threshold is the prescribed daily doses per year, but the exact value of
this threshold varies. In our analysis, we will compare two models based on
121 DDD and 181 DDD which represent the drug consumption for three and
six months. Each prescription available in the data set contains an ATC code
which allows us to classify it to a PCG.
Our analysis is based on the PCG classification currently used in Slovakia
(Ministry of Health, 2012) which we compared and further adjusted to the
Dutch classification (Lamers and van Vliet, 2004).
The Slovakian classification is also based on the PCG classification system used
in the study of Lamers and van Vliet (2004) (Table 2.1). Slovakian Ministry of
Health excluded from this classification some ATC codes for drugs which are not
available in Slovakia. On the other hand, in Slovakia some groups were added
which were found to correspond better to the health status of the Slovakian
population.
In our analysis, we kept updates made in PCG classification of Lamers and
van Vliet (2004) in case we did not find enough observations of individuals
classified in these chronic conditions i.e. Gout, Tuberculosis, and Peptic acid
disease was excluded. The group of Rheumatologic conditions was divided
into two subgroups which differs in the content of TNF inhibitors which treats
mainly rheumatoid arthritis. Respiratory illness, asthma is divided into two
groups of Severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and
Asthma, groups of Psychotic illness, Spinal cord and brain disease, Treatment
with growth hormone, Hormonal oncological treatment and Neuropathic pain
are set. We decided to keep Hypertension low, Hypertension high and Thyroid
disorders as in Lamers and van Vliet (2004). The updated PCG classification
which we use for our analysis is presented in the Table 5.4.
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Table 5.4: PCG classification





PCG1 Glaucoma S01E 1.593% 1.293%
PCG2 Thyroid disorders H03A,H03B 3.888% 2.625%
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PCG8 Asthma R03 excluding (R03AC18,
R03AK03, R03BB, R03CA02,
R03BC01, R03CC02, R03CC13)
if in PCG7 2.638% 2.028%
PCG9 Diabetes type II A10 if in PCG5,
PCG6 or PCG16
0.438% 0.361%





A07EA06, A07EC02 0.223% 0.173%














if in PCG13 0.307% 0.183%
PCG15 Parkinson’s disease N04B 0.258% 0.210%
PCG16 Diabetes type I A10A if in PCG6 0.234% 0.225%










PCG20 Malignancies L01 excluding (L01BA01),
L03AA, L03AC01, L04AX04
0.250% 0.184%










H01AC01, H01AC03 0.016% 0.015%
(Continued on next page)
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Table 5.4: PCG classification (continued)








PCG25 Neuropathic pain N01BX04, N03AX12, N03AX16, 0.204% 0.112%
PCG26 Hypertension - low C03A, C03EA01
C07
if in PCG6 5.422% 4.884%
PCG27 Hypertension - high C02, C08,
C09A, C09B
if in PCG6 8.930% 8.163%
Sum 47.26% 40.53%
Only the drugs mentioned in Table 5.4 are therefore indicative of chronic
conditions which are subsequently used to predicts future spending of people
classified in a category. The last two column of Table 5.4 present the prevalence
of the conditions in our sample for the two threshold 121DDD and 181DDD.
The most frequent disease in the population was Hypertension-high (more than
8%), followed by Hyperlipidemia and Hypertension - low. On the other hand,
Cystic fibrosis, HIV/AIDS and Treatment with growth hormone are among the
scarcest diseases.
Table 5.5 summarizes the number of PCGs per insuree.













An individual can be assign to one or more chronic conditions based on his
drug consumptions i.e. if he suffers from Diabetes and Hypertension - high,
he/she is classified in both PCGs, similar to the Netherlands. When the 121DDD
threshold is set, almost 70% of people is not assigned to any PCG. For the
181DDD threshold, it rises to more than 72%. Those not assigned to any PCGs
are categorized in a group ”no PCG” and this group is used as the reference
category in the model.
Chapter 6
Methodology
This chapter introduces the methodology used for the estimation and prediction
of health care expenditures in the demographic and PCG models.
6.1 Process of estimation
To assess the accuracy of the models for predicting future costs, the second
year of the sample is not included in the estimation of 6.1, 6.3 and 6.5 and is
used for comparison of the predictive power of estimated models. The process
follows in three steps:
1. models are fit to the estimation data set (year t)
2. estimated coefficients are, then, used to calculate predicted cost in year
t+1
3. the predicted costs are compared with the actual costs
We will compare the financial impact on individual insurance companies resulting
from the demographic and PCG models in 2012. Since we do not have data
on money allocated to each insurance company, the financial impact will be
approximated based on the share of insurees in 2012. We will use the real health
care costs incurred for our sample in 2012 as the amount for redistribution
among the insurance companies.
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6.2 Determination of the models
In all models included in our analysis, the dependent variable is the individual
health care expenditure, and the independent variables are dummy variables
defining different risk classes in the population. As mentioned in the Chapter
3.2 the insurance companies receive state payment for an insured each month.
Nevertheless, the cost indices are calculated once a year (in year t for year
t+1). These indices are then used to calculate monthly capitation payment
allocated to insurance companies. In our study we will keep the same method
of estimation, thus the models will be calculated on annual basis.
We compare three basic models.
6.2.1 Demographic model
The first type of model to be estimated is the model currently used in the Czech
Republic. It predicts health care expenditures based on the categorization of
each individual to age/sex groups. The demographic model is defined as:
costi = α + βsasex agei, (6.1)
where costi are health care costs for the i
th person and sex agei is the sa
th age/sex
group for the ith person. When the coefficients of the model are estimated,
expenditures for the next year will be predicted and compared to real historical
data.
Predicted cost for the demographic model (equation 6.1) for the year t+1 are
given by:
ˆcosti,t+1 = α̂t + β̂sa,tsex agei,t+1, (6.2)
where the coefficients α̂t and β̂sa,t are estimated by equation 6.1. The de-
mographic variables for the prediction of cost for year t+1 is also based on
the individual age in t+1 rather than t. As the insurance companies submit
the demographic data monthly to the Ministry of Health, it is possible to use
the current age structure to take advantage of the most up-to-date data in
the model e.g. a male 49 years old in year t was classified to the group of males
aged 45-49 years for the analysis of year t, for the prediction of health care costs
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in year t+1 he is classified to the group of 50-54 as he is 50 years old in year
t+1.
6.2.2 PCG model
The second model includes the same risk adjusters as equation 6.1 and adds
dummy variables indicating the presence of a chronic condition (PCG) based on
drug utilization in year t. It is defined as:
costt = α + βsasex agei + γxpcg xi, (6.3)
where costi are health care costs for the i
th person, sex agei is the sa
th age/sex
group for the ith person and pcg x is the xth PCG group for the ith person.
Predicted expenditures for the PCG model are determined as:
ˆcosti,t+1 = α̂t + β̂sa,tsex agei,t+1 + γ̂x,tpcg xi,t, (6.4)
where the coefficients α̂t, β̂sa,t and γ̂x,t are estimated by Equation 6.3. We use
again the individual age for the year t+1, contrary to 6.3 the PCG classification
is based on the consumption from the year t e.g. an individual who was classified
to a PCG in year t is also classified to the same PCG for the prediction of health
care cost in t+1. The demographic variables for the prediction of cost for year
t+1 are also based on the individual age in t+1, similar to Equation 6.2.
6.2.3 PCG and region model
The third model comprises the variables from equation 6.3 and adds regional
dummies. It is defined as:
costt = α + βsasex agei + γxpcg xi + δrregioni, (6.5)
where costi are health care costs for the i
th person, sex agei is the sa
th age/sex
group for the ith person, regioni is the r
th region of residence for the ith person
and pcg x is the xth PCG group for the ith person.
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Predicted expenditures for the PCG and regional model (6.5) are determined
as:
ˆcosti,t+1 = α̂t + β̂sa,tsex agei,t+1 + γ̂r,tregioni,t+1 + δ̂x,tpcg xi,t, (6.6)
where the coefficients α̂t, β̂sa,t and γ̂r,t are estimated by Equation 6.5. We use
again the individual age and also the region of residence for the year t+1 as
opposed to 6.5.
All models will be estimated using the OLS estimation approach on untrans-
formed data. All models are therefore assumed to be linear in the coefficients
and include an intercept. They are estimated by means of WLS where the
regression weights are a function of individual eligibility in the given period.
The prediction which best reflects the reality will be determined as the most
efficient model from equations 6.1, 6.3 and 6.5. As one of the objectives of
our analysis is to develop a method of risk adjustment that might be put into
practice by the regulators and policymakers, the advantage of the WLS models
is that they are easier to use and to interpret than other models.
6.3 Model evaluation
Efficiency of a particular model is based on its predictive performance at the
population as a whole evaluated by the three measures described in sections
6.3.1-6.3.4. Additionally, we examine how well the model predicts health care
costs for different cost sub-groups in the population.
6.3.1 R2
The parameter R2 measures the percent of individual variance explained by
the model and indicates how much of the variance in the dependent variable is





where SSE is the explained variation and SST is the total variation. The higher
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the R2 value, the higher the predictive performance of the model. The parameter
R2 will evaluated the models at the population level.
6.3.2 MAPE
Mean Absolute Prediction Error (MAPE) is calculated as the average of the
absolute differences between predicted and observed health care costs (Van de






|Ci − Ĉi| (6.8)
where Ci is the actual costs, Ĉi the costs predicted by the model and n is
the number of individuals in the sample. Using the absolute value means
that predictions that are greater or less than actual costs cannot cancel each
other out. Lower MAPE-values indicate a higher predictive performance of the
model.
6.3.3 MARE
Mean Absolute Relative Error (MARE) captures the relative accuracy of a predic-
tion and is defined as the average of the absolute differences between predicted









Because some subjects have no costs in the forecast year, we add a value of 1 to
actual costs for all subjects to avoid undefined ratios. The MARE is a relative
measure that expresses errors as a percentage of the actual data. This is its
greatest advantage as it provides an easy and intuitive way of judging the extent
or importance of errors. As it is a relative number without dimensions, the
comparison of the model is straightforward. A risk instrument’s forecast power
is evaluated by the degree its MARE closer to 0. The lower MARE the model
has, the more accurate the model is.
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6.3.4 Cost quintile analysis
Risk instruments may generate more accurate predictions for different ranges of
the cost distribution. We evaluate the relative strength of the PCG model to
predict costs for relatively high, medium, and low-cost subjects by examining
the predictive performance of the model by cost quintile. Subjects are grouped
into five equally populated segments based on their actual costs, and the values
of MAPE and MARE are compared. The MAPE and MARE measures survey
subgroups and can provide a good indication of the extent to which models
compensate insurers for differences in expenses between cost subgroups. Certain
models may overpredict low-cost groups or underpredict high-cost groups more
significantly. This method is also applied in studies Fishman and Shay (1999);
Fishman et al. (2003); Van de Ven et al. (2014).
Chapter 7
Results
This chapter discusses the results of our analysis. Firstly, it comments and
compares the results obtained for each risk adjustment model. Secondly, the
impact of selected model on the insurance companies is calculated.
7.1 Model estimation
In this section, we present the results of models 6.1-6.6 that we analyzed in
detail. Table 7.1 summarizes the variables included in each model and the DDD
threshold for classifying a patient to a PCG group. We assigned a number 1-6
to each model to better distinguish between them when displaying their results.








Model 1 6.1 & 6.2 Demographic model 36 age/sex groups -
Model 2 6.1 & 6.2 Demographic model 38 age/sex groups
(age 0 added)
-
Model 3 6.3 & 6.4 PCG 38 age/sex,
27 PCG groups
181DDD
Model 4 6.5 & 6.6 PCG+regions 38 age/sex, 27 PCG,
8 region groups
181DDD
Model 5 6.3 & 6.4 PCG 38 age/sex,
27 PCG groups
121DDD




The number of variables included in the model for age/sex and region groups
is always one less than the number of defined risk classes because of perfect
multicollinearity if otherwise. All 27 PCG groups are included in the regressions
as their reference category is no PCG, the case when an individual was not
assigned to any chronic condition based on one’s past consumption.
The estimation results of the models for the year t (2011) are displayed in Table
7.2.
Table 7.2: Estimation results - validation period 2011
Variable Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
M 0y 32 746 ** 33 712 ** 33 581 ** 33 991 ** 33 859 **
M 1-4 6 032 ** -98 510 430 706 624
M 5-9 -796 ** -796 -712 -757 -585 -632
M 10-14 -672 -672 -847 -851 -826 -831
M 15-19 -2 220 -2 220 ** -2 233 ** -2 240 ** -2 152 ** -2 159 **
M 20-24 -3 279 ** -3 279 ** -3 631 ** -3 673 ** -3 507 ** -3 551 **
M 25-29 -2 393 ** -2 393 ** -3 203 ** -3 294 ** -3 105 ** -3 198 **
M 30-34 -1 371 ** -1 371 ** -2 601 ** -2 718 ** -2 525 ** -2 643 **
M 35-39 -371 ** -371 -2 162 ** -2 251 ** -2 252 ** -2 342 **
M 40-44 1 614 1 614 ** -872 -956 -937 -1 023
M 45-49 4 279 ** 4 279 ** 289 219 191 119
M 50-54 9 136 ** 9 136 ** 3 021 ** 2 974 ** 2 575 ** 2 524 **
M 55-59 17 066 ** 17 066 ** 7 254 ** 7 184 ** 6 542 ** 6 469 **
M 60-64 24 681 ** 24 681 ** 11 136 ** 11 050 ** 10 057 ** 9 966 **
M 65-69 33 013 ** 33 013 ** 15 637 ** 15 516 ** 14 136 ** 14 010 **
M 70-74 39 537 ** 39 537 ** 18 825 ** 18 724 ** 16 435 ** 16 330 **
M 75-79 44 849 ** 44 849 ** 21 515 ** 21 407 ** 18 727 ** 18 613 **
M 80-85 47 738 ** 47 738 ** 23 385 ** 23 246 ** 20 397 ** 20 251 **
M 85up 48 191 ** 48 191 ** 24 894 ** 24 670 ** 22 292 ** 22 059 **
F 0y 30 407 ** 31 447 ** 31 315 ** 31 724 ** 31 590 **
F 1-4 5 035 ** -951 -184 -260 29 -48
F 5-9 -2 534 ** -2 534 ** -2 281 ** -2 332 ** -2 074 ** -2 126 **
F 10-14 -1 131 ** -1 131 -1 210 -1 223 -1 156 -1 170
F 20-24 -457 -457 -773 -802 -748 -777
F 25-29 2 612 2 612 ** 1 660 ** 1 560 ** 1 633 ** 1 532 **
F 30-34 4 020 ** 4 020 ** 2 500 ** 2 377 ** 2 408 ** 2 284 **
F 35-39 3 637 ** 3 637 ** 1 281 ** 1 194 ** 1 158 ** 1 070
F 40-44 4 100 ** 4 100 ** 644 576 400 332
F 45-49 6 919 ** 6 919 ** 1 799 ** 1 723 ** 1 370 ** 1 293 **
F 50-54 10 360 ** 10 360 ** 3 088 ** 3 043 ** 2 386 ** 2 340 **
F 55-59 13 956 ** 13 956 ** 3 829 ** 3 757 ** 2 817 ** 2 743 **
F 60-64 18 458 ** 18 458 ** 5 517 ** 5 422 ** 4 159 ** 4 063 **
F 65-69 24 575 ** 24 575 ** 7 584 ** 7 460 ** 5 997 ** 5 871 **
F 70-74 30 651 ** 30 651 ** 10 756 ** 10 687 ** 8 685 ** 8 615 **
F 75-79 36 735 ** 36 735 ** 13 883 ** 13 796 ** 11 292 ** 11 201 **
F 80-85 39 512 ** 39 512 ** 15 545 ** 15 404 ** 12 610 ** 12 464 **
F 85up 41 745 ** 41 745 ** 18 917 ** 18 749 ** 15 839 ** 15 664 **
Intercept 10 330 ** 10 330 ** 9 269 ** 8 683 ** 8 967 ** 8 453 **
PCG 1 4 896 ** 4 780 ** 5 264 ** 5 162 **
(Continued on next page)
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Table 7.2: Estimation results (Continued)
Variable Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
PCG 2 4 415 ** 4 340 ** 3 853 ** 3 788 **
PCG 3 46 249 ** 46 279 ** 43 031 ** 43 055 **
PCG 4 20 165 ** 20 079 ** 19 694 ** 19 609 **
PCG 5 7 498 ** 7 431 ** 7 178 ** 7 104 **
PCG 6 23 564 ** 23 654 ** 22 927 ** 23 019 **
PCG 7 38 711 ** 38 690 ** 34 201 ** 34 194 **
PCG 8 16 810 ** 16 776 ** 15 234 ** 15 202 **
PCG 9 7 202 ** 7 235 ** 7 186 ** 7 219 **
PCG 10 31 286 ** 31 327 ** 28 303 ** 28 340 **
PCG 11 14 571 ** 14 580 ** 10 299 ** 10 306 **
PCG 12 35 614 ** 35 704 ** 34 021 ** 34 110 **
PCG 13 338 557 ** 338 411 ** 324 573 ** 324 424 **
PCG 14 39 802 ** 39 863 ** 29 561 ** 29 651 **
PCG 15 29 923 ** 29 932 ** 24 418 ** 24 424 **
PCG 16 45 802 ** 45 862 ** 45 548 ** 45 605 **
PCG 17 135 265 ** 135 241 ** 119 484 ** 119 462 **
PCG 18 448 431 ** 448 411 ** 421 751 ** 421 813 **
PCG 19 209 259 ** 209 207 ** 186 144 ** 186 106 **
PCG 20 441 534 ** 441 511 ** 380 126 ** 380 110 **
PCG 21 206 401 ** 205 832 ** 196 849 ** 196 287 **
PCG 22 848 523 ** 848 465 ** 807 401 ** 807 340 **
PCG 23 238 110 ** 238 094 ** 225 440 ** 225 438 **
PCG 24 49 050 ** 48 986 ** 48 334 ** 48 265 **
PCG 25 53 015 ** 52 955 ** 46 686 ** 46 662 **
PCG 26 4 880 ** 4 939 ** 4 513 ** 4 579 **
PCG 27 3 712 ** 3 786 ** 3 641 ** 3 724 **
CZ01 3 170 ** 3 099 **





CZ08 1 208 ** 1 104 **
R2 0.0207 0.0283 0.1851 0.1853 0.1947 0.1948
Note: Significance codes * p-value< 0.1 ; ** p-value < 0.05
The R2 of the models predicting the total cost for year t ranged from 0.0207 to
0.1948. In the models which control for demographic measures, the R2 was the
lowest: 0.0207 for the model used currently and 0.0283 for the model when the
groups of newborn (up to one year) male/female were added. The PCG models
reported higher R2. The model based on 181DDD reached the R2 of 0.1851.
When the region dummies added, the R2 rose only by 0.02 to 0.1853. A similar
result was found for the PCG model based on 121DDD threshold which reported
the R2 of 0.1947 and 0.1948 for the PCG region model.
Not all the age groups turned out to be significant in the demographic, nor the
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PCG models (for Model 3 to 6 the insignificant groups were males aged 1-4,
10-14, 40-44 and 45-49 years and females aged 1-4, 10-14, 20-24, 35-39 and 40-44
years). Therefore, we tested models with age groups defined differently. We
clustered the insignificant groups into 10-20 years instead of 5 years, but all the
models estimated costs in year t as well as the predictive models for expenditures
in year t+1 performed worse. Thus, we kept the logic of the demographic model
currently used and age variables in all models are grouped by five years except
the significant group of newborns. All of the PCG regression coefficients are
significantly different from zero (p-value=0.000). Only three regions’ coefficients
turned out to be significant with p-value<0.05. Moreover, the contribution of
adding the region variables to the PCG model is low. The R2 rose only by
0.01 and 0.02 for PCG model based on 181DDD and 121DDD, respectively. It
suggests the region variables are not valid risk adjusters of health care costs in
the Czech Republic.
The intercept of a model represents the health care cost for the reference groups
of the model. i.e in PCG model a women aged 15-19 years and classified in
no PCG. The highest intercept is reached for the demographic models (10 330
CZK), the lowest values are reported by the region PCG models based on
121DDD (8 452 CZK). As all variables are dummy variables, their coefficients
represent the cost of a patient who is classified (dummy=1) to demographic,
region or PCG group. When the coefficients for risk groups are reported, we
need to consider the value of intercept as well e.g. for a male aged 20-24 years
the average cost is 10 330 - 3 279 = 7 051 CZK. The most expensive individuals
with regard to age are males 85 years and older. Their health care cost are
estimated at more than 48 000 CZK for demographic models, at 24 000 CZK
for PCG model based on 181DDD and more than 22 000 CZK for the PCG
model based on 121DDD. The least expensive group are the males 20-24 years
old which cost less than -3 000 CZK.
Among all chronic conditions, Renal disease (PCG 22) is associated with the
highest health care costs (more than 807 000 CZK for all models), following by
Cystic fibrosis (PCG 18) with more than 420 000 CZK and Malignancies (PCG
20) incurring health care cost of more than 440 000CZK for Model 3 and 4 and
380 000 CZK for Model 5 and 6. Among the chronic groups that incur up to
5 000 CZK are Hypertension - high (PCG 27), Thyroid disorders (PCG 2) and
Glaucoma (PCG 1). The coefficients of PCG are generally higher in the model
based on 181DDD as only patients with more severe condition (higher number
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of DDD) are classified to a chronic group.
In our analysis, the main criterion for evaluation of the models is how well it
predicts the future health care cost, thus we focus on the predictive power of
the models for the year t+1 (2012). The predictive performance was assessed
and compared at both the population and the cost quintile level. By doing so,
it is possible to examine how well the models predict expenses for the total
sample and different cost sub-populations.
Table 7.3 shows the R2, MAE and MARE for the prediction models of health
care expenditures in year t+1.
Table 7.3: Evaluation of models for year t+1
R2 MAPE (SD) MARE (SD)
Model 1 0.0203 22 709 (118 704) 178.88 (1 929)
Model 2 0.0206 23 227 (118 933) 176.65 (2 004)
Model 3 0.1295 19 856 (115 934) 117.48 (1 295)
Model 4 0.1297 19 853 (115 929) 122.78 (1 347)
Model 5 0.1387 19 775 (115 685) 111.61 (1 229)
Model 6 0.1389 19 770 (115 680) 116.94 (1 280)
The models for the year t+1 had lower predictive R2 than the prediction models
for year t as supposed. No more than 14% of the variations in the total cost
for t+1 was explained. Although these R2 values might seem low, they are
consistent with empirics. Van Vliet (1992) concluded that no more than 20%
of the variations are predictable on an individual basis. Fishman et al. (2003)
argues that the maximum explainable R2 for risk assessment models may be
approximately 30%. Risk-based forecast produced relatively low R2 because
a large portion of health care costs occur randomly and cannot be predicted with
great confidence. There are outliers with extremely high costs in our sample
which are not predicted adequately by the risk adjusters and therefore lead to
lower R2. The high-cost patients are controlled for only when they classify to
a PCG. Around 70% of individuals do not classify in any PCG (see Table 5.5)
and for those individuals we do not have any other health status proxy which
would capture their health conditions. We suppose them to be in ”good health”
and they are risk adjusted only by demographic variables.
Demographic risk instrument explains relatively little of the variance in cost in
year t+1 with an R2 of 0.0206. Poor predictive power of these models is also
confirmed by large values of MAPE and MARE. R2 increases to almost 0.13
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and the MAPE decreases when the PCG groups are added with the threshold
of 181DDD. When the threshold value for the PCG model is set to 121DDD,
a remarkable improvement in the predictive power is reached: R2 of 0.1387,
MAPE 19 775 CZK and the MARE of 111.61. The results also confirmed that
adding the region risk adjusters does not improve considerably the predictive
power of the PCG models. The R2 value rose only by 0.02 when the region
variables added to the PCG models.
7.2 Cost quintile analysis
Table 7.4 shows model performance for five quintiles of health care cost in 2012.
The first row for each quintile represents the mean actual value of health care
costs (in CZK) for the year 2012 and its standard deviation for this quintile.
Then the predicted mean health care cost per quintile is calculated for each model
as well as the values for MAPE and MARE. We consider a prediction model
more efficient when the mean per quintile is closer to the actual mean value and
again the values of MAPE and MARE are low (the lower, the better).
The demographic models tend to over-predict low cost (quintiles 1-4) and under-
predict high cost (quintile 5) enrollees significantly. The reason is demographic
models have larger intercepts and higher coefficients for the demographic groups
than the PCG models (see Table 7.2) resulting in over-prediction of low cost and
under-prediction of high-cost enrollees. The risk adjustment for demographic
models is established only through means of age and sex and does not take into
account other factors which determine the health care cost. Chronic conditions
are therefore more accurate risk instrument when we evaluate predicted mean
for the quintiles.
When comparing the PCG models, PCG model based on 121DDD predicts
mean health care expenditures better than PCG models based on 181DDD with
few exceptions e.g. for the prediction of mean for the fourth quintile, but the
difference is small (17 CZK difference in means between the models 3 and 5).
The greatest difference among PCG models occurs in the most expensive cost
quintile where the mean prediction by the PCG model based on 181DDD is
41 789CZK whereas 43 011 for the PCG model based on 121DDD. On the other
hand, when models are compared relatively in the 5th quintile PCG model
(181DDD) turns out be by 0.02 more accurate.
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Table 7.4: Model performance: Cost quintile analysis
Quintile Model Mean (SD) MAPE (SD) MARE (SD)
1st Actual value 1 223 (602)
Model 1 13 918 (8 712) 12 695 (8 710) 887.53 (4 240)
Model 2 13 936 (9 424) 12 713 (9 420) 876.42 (4 412)
Model 3 9 755 (5 064) 8 529 (5 060) 583.43 (2 853)
Model 4 9 766 (5 180) 8 539 (5 187) 609.99 (2 966)
Model 5 9 349 (5 008) 8 122 (5 003) 554.12 (2 706)
Model 6 9 359 (5 118) 8 133 (5 123) 580.84 (2 818)
2nd Actual value 3 322 (666)
Model 1 15 261 (9 214) 11 939 (9 181) 3.74 (2.97)
Model 2 14 829 (10 442) 11 507 (10 421) 3.61 (3.33)
Model 3 10 983 (6 184) 7 661 (6 158) 2.41 (1.98)
Model 4 10 934 (6 259) 7 612 (6 233) 2.39 (2.01)
Model 5 10 653 (6 387) 7 331 (6 358) 2.30 (2.02)
Model 6 10 604 (6 454) 7 282 (6 426) 2.29 (2.04)
3rd Actual value 6 485 (1 255)
Model 1 18 744 (11 603) 12 279 (11 517) 1.97 (1.87)
Model 2 18 495 (13 908) 12 030 (13 815) 1.92 (2.2)
Model 3 14 467 (11 016) 8 111 (10 818) 1.29 (1.67)
Model 4 14 447 (11 037) 8 135 (10 806) 1.29 (1.67)
Model 5 14 220 (11 445) 7 894 (11 232) 1.25 (1.74)
Model 6 14 200 (11 458) 7 923 (11 210) 1.25 (1.74)
4th Actual value 13 548 (3 248)
Model 1 23 818 (14 132) 12 566 (12 177) 0.98 (1.03)
Model 2 24 448 (18 201) 13 574 (16 305) 1.05 (1.33)
Model 3 21 910 (19 731) 12 133 (17 499) 0.92 (1.35)
Model 4 21 921 (19 731) 12 163 (17 482) 0.92 (1.35)
Model 5 21 927 (20 648) 12 365 (18 351) 0.93 (1.4)
Model 6 21 936 (20 637) 12 390 (18 324) 0.93 (1.4)
5th Actual value 87 152 (262 670)
Model 1 30 238 (15 718) 64 067 (260 521) 0.54 (0.3)
Model 2 30 998 (22 523) 66 308 (260 282) 0.61 (0.44)
Model 3 41 789 (65 966) 62 824 (253 696) 0.64 (0.67)
Model 4 41 837 (65 962) 62 795 (253 689) 0.64 (0.67)
Model 5 43 011 (67 685) 63 138 (252 955) 0.66 (0.71)
Model 6 43 056 (67 674) 63 100 (252 949) 0.66 (0.71)
Thus, generally the differences in the prediction accuracy for the cost quintiles
between 121DDD and 181DDD PCG models are small, but the PCG model
of 121DDD slightly outperform the other models. We can also conclude that
adding the region adjusters does not bring any significant improvement in the
prediction accuracy, neither in the overall nor quintile analysis.
7.3 Impact on the insurance funds
Table 7.5 shows the financial impact of PCG model (121DDD) implementation
on the insurance companies when compared to the allocation of the amount by
the current demographic model.
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111 69 413 395 100.46%
201 -3 012 622 99.76%
205 -24 153 087 98.35%
207 -18 783 776 98.64%
209 7 654 229 102.68%
211 -1 241 633 99.95%
213 -23 155 784 97.13%
217 -6 720 720 99.15%
The greatest impact in terms of CZK would be on Všeobecná zdravotńı
pojǐsťovma (VZP - 111) which would receive more than 69 million (0.46%).
Zaměstnanecká pojǐstovna Škoda (209) would also improve its financial position
by more than 7 million. The rest of the insurance companies would earn less,
the most substantial loss of 23 million (-2.87%) would suffer Rev́ırská bratrská
pokladna (213).
In recent years, VZP suffered from financial problems. It is due to its distribution
of insurees who are older and more ill compared to other insurance companies
(see Table 5.3). In 2013, the Ministry of Health granted an interest-free loan
to VZP amounting 1.7 billion CZK. The first part (0.7 bil.) was repaid last
year; the rest should be pay off in years 2015 and 2016. Therefore increasing its
revenues systematically should be the intention of our political representation.
The establishment of the PCG model as the risk adjustment model is one of
the possibilities how to allocate the financial resources more equitably among
the insurance companies and therefore prevent their financial problems.
Chapter 8
Discussion
Our main contribution is that we confirmed that PCG model is a valid risk
adjuster for individual health status in the Czech Republic. An increase of R2
from 0.0203 for the demographic model currently used to 0.1387 for the PCG
model based on 121DDD is significant improvement in model performance. We
analyzed the performance of models on a large sample; therefore inferences from
our analysis can be assumed to be valid for the whole population as well. We
suggested a model that is easy to implement in reality and could be use by the
Ministry of Health for risk adjustment in the Czech Republic.
The empirical analysis and the data used illustrated the potential for improv-
ing the predictive performance of the risk adjustment model in health care.
The results of our analysis confirm that the PCGs contribute significantly to
the prediction of individual expenditures. The main reason PCG model out-
performs the demographic model is that PCG model uses the information on
individual health condition to create risk categories. The demographic model
assumes that everybody of the same age and sex incurs similar health care
expenditures, which does not hold in reality.
Adding PCGs to the demographic model brings additional details about indi-
vidual health status. When they are not assigned to any PCG group, they are
supposed to be in good health and vice versa. We report in Table 5.5 that
about 30% of enrollees in our sample (depending on the DDD threshold) classify
into a PCG category. Any such information about health condition except sex
and age is missing in the demographic model.
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PCG model with regional variables does not increase the predictive power of the
PCG model. As mentioned in the Chapter 4.1.3, the region information was not
available for all cases. Statistical significance was not convincing neither; thus
we do not believe the region risk classes should be used in the model for risk
adjustment in the Czech Republic. One of the reasons that the region adjusters
do not play a role in the models might be that people have official permanent
address to the actual place of residence. The regional health differences are
probably captured by demographic and morbidity variables as well. Therefore,
the regional variables turn out to be insignificant.
For the case of PCG groups, a statistical significance should not be the exclusive
condition about a model evaluation. When risk adjustment is based on previous
drug consumption, there is always the danger of adverse selection and of
rewarding inefficient providers. The reason is that the providers might be
encouraged to more drug utilization than is strictly necessary (Lamers and
Vliet, 2003). An individual who is assigned to one or more of the PCGs
gives an advantage to the insurance fund to receive higher capitation payment,
therefore in theory it would be financially advantageous for the fund to stimulate
the prescription of drugs that fall into the PCG system. The Ministry of
Health initiated projects in last years for the reduction of expenditures on drug
prescription e.g. they supported the prescription of drugs with lower cost when
generic substitutes (Ministerstvo zdravotnictvi CR, 2007). These initiatives to
reduce costs of prescribed drugs while maintaining the quality of care should
not be spoiled by contrary incentives of the risk adjusted capitation payments
system.
To prevent gaming in prescription of drugs, we used the number of DDD instead
of number of prescriptions which was also used in earlier studies (Lamers and
Vliet, 2003; Prinsze and van Vliet, 2007). Using DDD eliminates the possible
form of manipulation in this context e.g. a patient could receive four times
a prescription for 1 week instead of a prescription for whole month. When the
results of PCG models based on 121DDD and 181DDD in terms of R2 differs only
by 1%, we might also consider the threshold of 181DDD. A higher threshold is
less prone to gaming as it is harder to reach it by stimulation of prescriptions.
No risk assessment model can eliminate gaming, but every risk model should
at least increase the cost of gaming. Gaming a PCG model by dispensing
drugs that are not necessarily medically indicated involves costs to both the
health insurance company and patient (if copayments apply) and also potential
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health risks to the patient. As 121DDD represent a prescription of drugs for four
months, we think it is sufficient level for the risk-adjustment model to prevent
gaming.
When considering the application of the PCG model in reality, its important
advantage is simple implementation. Cost and drug consumption information
from previous years is, in most situations, already available in the administrative
files of insurers and Ministry of Health. This means that it does not require
a large additional administrative burden for collecting this information. Thus,
regulators and policymakers could relatively easily improve the predictive per-
formance of currently used models by including chronic condition information
based on the drug consumption from prior years.
Chapter 9
Conclusion
Czech Ministry of Health is currently modeling the risk costs of insurance
companies based on a demographic model. Such model takes into account
demographic characteristics of the enrollees only, i.e. age and gender. Unfortu-
nately, the demographic model does not yield much convincing results, achieving
the explanatory power of 2%. This causes inefficiencies in government funds’
allocation among insurance companies in the Czech Republic, since the model
underestimates the costs of insurers with a large proportion of chronically ill
enrollees. This leads to risk selection - insurers prefer to insure rather healthy
patients and receive the same funds.
Recent research and experience from abroad (Netherlands, Slovakia) have shown
that adding pharmacy-based cost groups adjusters into the model significantly
improves its predictive power and would thus mitigate government funds allo-
cation inefficiencies. Moreover, adding so-called regional risk adjusters could
further upgrade the health care risk adjustment model in use. However, health
care systems across countries tend to be very specific and the same frameworks
might thus not be applicable globally. On contrary, each risk cost model’s
adjustment needs to be tested for carefully, taking into consideration local
specifics.
The aim of this thesis was to test for PCG and regional risk adjusters in
the context of the Czech health care system. Our analysis has shown that
PCG adjusters notably upgrade the existing risk costs model, since they are
able to account for the group of pharmaceuticals each individual is prescribed.
This in turn makes the health care risk costs assessment more accurate and
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helps improve funds’ allocation to insurance companies. Therefore, we strongly
recommend to include these PCG adjusters into the model of the Ministry of
Health of the Czech Republic. Regional risk adjusters could further improve the
model as they control for the region the enrollee comes from and thus account
for region-specific effects on the health care costs, e.g. air pollution. Quite
surprisingly, regional risk adjusters did not help improving the model’s power
and are thus seen as redundant. We suppose that the regional specifics are
already captured in the individual health status defined by PCG.
The performance of the models was tested using a sample of 1 058 197 observa-
tions representing 10% of the Czech population in 2011 and 2012. The PCG
classification included 27 chronic conditions. The models were estimated by
WLS where the weight was a function of individual eligibility in the estimation
period. Three types of model were assessed: demographic model, PCG model
and PCG including region adjusters. Furthermore, two thresholds of 121 DDD
and 181 DDD for classifying to the PCG were set and the performance of
the PCG models was mutually compared. The model performance for predict-
ing the health expenditures in the next year was evaluated by R2 parameter.
Its value increased from 2.03% for the demographic model currently used to
0.0206% when the age group of newborns was added to the model. The PCG
models performed significantly better. The R2 of PCG model based on 121DDD
increased to 13.87%, and when the threshold of 181 DDD was set, the R2
decreased little to 12.95%. The higher threshold for the PCG means that fewer
people classify to a chronic condition. As the R2 of the model is higher, the
best model for predicting the health care expenditures is the PCG model with
121 DDD threshold.
These high R2 values demonstrate that PCG model is able to predict more
accurately individual health care costs than demographic model. We concluded
that adding the PCG variables to the risk adjustment model increases its
predictive performance which is in line with conclusions of other studies.Quite
surprisingly, the regional risk adjusters did not bring any significant improvement
of the model performance. The R2 value for the PCG model including regional
adjusters was 12.97% for the 181 DDD threshold and 13.89% for the 121 DDD
threshold, almost equal values to PCG model. Thus, we do not recommend to
include region adjusters into the risk adjustment model.
This thesis makes three important contributions to the literature dealing with
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PCG models. First, we updated the PCG classification of Lamers and van Vliet
(2004) by including new disease categories which are appropriate to capture
morbidity conditions for the Czech population. Second, we added two new
demographic groups, male and female newborns, as their actual mean health
care costs are significantly different from the other children up to 5 years old.
Third, we assessed the predictive performance of the PCG model based on 121
DDD and 181 DDD threshold and compared the results to the demographic
model currently used in the Czech Republic.
There are several potential improvements to the risk adjustment model in the
Czech Republic that are worth further research. It is expected that cost and
diagnostic information from multiple prior years could further improve models’
predictive performance. Therefore, the definition and classification of diagnostic
groups could be investigated. Moreover, the number of years of lagged cost and
diagnostic information could be explored to find what is the relevant period to
be included in the risk adjustment model.
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